An HIV-infected patient with very low atazanavir (ATV) plasma trough concentrations despite clinical signs of poor drug tolerability was described. By therapeutic drug monitoring (TDM), the authors found that the patient had an atypical ATV pharmacokinetics characterized by rapid drug absorption followed by very fast drug clearance probably attributable to his genetic background. This case underlines the importance of traditional and pharmacogenetic-based TDM for the individualization of ATV therapy in HIV-1 patients.
Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient / D. Cattaneo, P. Meraviglia, V. Cozzi, S. Baldelli, G. Milani, E.G.I. Clementi. - In: FUNDAMENTAL & CLINICAL PHARMACOLOGY. - ISSN 0767-3981. - 26:2(2012 Apr), pp. 204-206.
Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient
E.G.I. Clementi
2012
Abstract
An HIV-infected patient with very low atazanavir (ATV) plasma trough concentrations despite clinical signs of poor drug tolerability was described. By therapeutic drug monitoring (TDM), the authors found that the patient had an atypical ATV pharmacokinetics characterized by rapid drug absorption followed by very fast drug clearance probably attributable to his genetic background. This case underlines the importance of traditional and pharmacogenetic-based TDM for the individualization of ATV therapy in HIV-1 patients.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
